Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.35 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL2973802 | 0.94 | SLC7A5 (0.58) | SLC7A5PTGS1SLC7A11SLC1A2SLC1A3 | |
| Leucine SCHEMBL2973800 | 0.94 | SLC7A5 (0.58) | SLC7A5PTGS1SLC7A11SLC1A2SLC1A3 | |
| Isoleucine SCHEMBL3374935 | 0.93 | PTGS1 (0.53) | SLC7A5PTGS1SLC7A11SLC1A2SLC1A3 | |
| Leucine SCHEMBL27464995 | 0.93 | SLC7A5 (0.60) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL3495955 | 0.91 | SLC7A5 (0.62) | SLC7A5PTGS1SLC7A11SLC1A2SLC1A3 | |
| Leucine SCHEMBL3497003 | 0.87 | SLC7A5 (0.44) | SLC7A5PTGS1SLC7A11SLC1A2SLC1A3 | |
| Isoleucine SCHEMBL3371099 | 0.87 | PTGS1 (0.47) | SLC7A5PTGS1SLC7A11SLC1A2SLC1A3 | |
| Leucine SCHEMBL27712713 | 0.87 | SLC7A5 (0.53) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL8021495 | 0.87 | SLC7A5 (0.53) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL8021491 | 0.87 | SLC7A5 (0.53) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143364-A1 | Chimeric Antibodies, Compositions and Methods for Treating Cocaine-Related Disorders | VYBION, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143364-A1 | Chimeric Antibodies, Compositions and Methods for Treating Cocaine-Related Disorders | CES2, CHRNA5, CHRNA3 | SLC7A5 4325/4885PTGS1 4848/4885SLC7A11 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.